CoinShares XBT Provider AB
16.3.2026 08:00:00 CET | Globenewswire | Press release
CoinShares XBT Physical Staked Polkadot - SEK Securities – Sharing of Staking Rewards
CoinShares XBT Physical Staked Polkadot - SEK Securities – Sharing of Staking Rewards
16 March 2026
CoinShares XBT Provider AB (publ)
Exchange Traded Products Programme for the issue of
CoinShares XBT Provider Digital Securities
LEI: 549300HGWKR2Q5T8GK64
CoinShares XBT Physical Staked Polkadot - SEK Securities – Sharing of Staking Rewards
Sweden – 16 March 2026 - CoinShares XBT Provider AB (publ) (the “Issuer”) hereby announces in accordance with Condition 5.6(b) of the Conditions of the CoinShares XBT Provider Digital Securities that, from start of trading on 16 March 2026, Staking Rewards in relation to the Staking Class (the “Specified Class”) specified below will be decreased from 5% per annum to 2.5% per annum. There will continue to be a positive increase in the daily accrual to the Coin Entitlement (in addition to the pre-existing reduction in management fee to 0% p.a.) which shall apply from the start of trading on 16 March 2026 until further notice in accordance with Condition 5.6(b).
| Specified Class | ISIN | Management Fee | Old Staking Reward | New Staking Reward |
| CoinShares XBT Physical Staked Polkadot - SEK | SE0025010838 | Reduced to 0% p.a. | 5% p.a. | 2.5% p.a. |
Terms used in this announcement and not otherwise defined bear the same meanings as defined or used in the base prospectus of the Issuer dated 12 March 2026.
For further information, please contact:
CoinShares XBT Provider AB (publ)
Artillerigatan 6,
114 51 Stockholm
Sweden
ir@coinshares.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom